Floatz logo

Donanemab

Autosomal Dominant Alzheimers Disease

Banner Healthmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Autosomal Dominant Alzheimers Disease cohort.

Asset / SponsorPhaseRating
RG6289
Banner Health
Phase 2/3B
Gnrh
Nelly Pitteloud
Phase 2/3CCC
Gonadotropin-Releasing Hormone
Nelly Pitteloud
Phase 2/3CCC
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION
Nelly Pitteloud
Phase 2/3CCC
FLAVONE, 3,3',4',5,7-PENTAHYDROXY-
Washington University School of Medicine
Phase 2CCC

View all 26 →

Same molecule, other indications

Donanemab is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
70 / 100
View asset →
Down syndromeDormant
BB
Indicative ·
65 / 100
View asset →
APP-related brain and vascular amyloidosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →